# Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

> **NCT04596150** · PHASE2 · COMPLETED · sponsor: **CytomX Therapeutics** · enrollment: 125 (actual)

## Conditions studied

- Neoplasms
- Breast Neoplasms
- Breast Neoplasms, Triple-Negative
- Breast Cancer
- Breast Neoplasms, Hormone Receptor Positive/HER2 Negative

## Interventions

- **DRUG:** CX-2009
- **DRUG:** CX-072

## Key facts

- **NCT ID:** NCT04596150
- **Lead sponsor:** CytomX Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-29
- **Primary completion:** 2023-06-02
- **Final completion:** 2023-06-02
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04596150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04596150, "Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04596150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*